Dr Daniel Vorobiof is a speaker at the SCFSA Skin Cancer Update.

Topic: Biological Therapies for Metastatic Melanoma


The last thirteen years have witnessed a dramatic evolution in the treatment of patients with Stages 2-4 malignant melanoma with the development of immune checkpoint blockade strategies targeting the PD-1 and CTLA-4 co-inhibitory receptors and MAP kinase (MAPK) molecular targeted therapy directed at oncogenic BRAF and MEK signaling pathways.
Prior to 2010, the only FDA-approved treatments for advanced melanoma were dacarbazine (DTIC) and high-dose interleukin-2.

In 2010, the results of the first trial of the BRAF inhibitor vemurafenib were published and the same year the results of the first trial of the anti-CTLA-4 monoclonal antibody, ipilimumab, were published demonstrating improved overall survival.

Since then nearly a dozen new single-agent treatments and treatment regimens for Stage 2-4 melanoma, have been approved by the FDA, including 4 systemic immunotherapy treatments/combinations (ipilimumab, nivolumab, pembrolizumab, combination ipilimumab-nivolumab), single-agent BRAF inhibitors (vemurafenib, dabrafenib), combination BRAF-MEK inhibitor regimens (dabrafenib-trametinib, vemurafenib-cobimetinib, encorafenib-binimetinib), and 1 intra-lesional immunotherapy involving a modified oncolytic herpes virus (talimogene laherparepvec, T-VEC).

A general description of the above-mentioned treatments and trials will be discussed as well as updated guidelines.


Medical Director


Founder and Medical Director

Sandton Oncology Centre, Johannesburg, South Africa (1989–2018)


National University of Córdoba Medical School, Argentina

Medical degree (MD)
Sealy-Falkson Award (2018)

Gynaecological Oncology Award from the Department of Gynaecology at the University of the Witwatersrand, Johannesburg, South Africa (2008)

Dr Daniel Vorobiof History and accolades

Dr Vorobiof has a MD degree from the University of Cordoba, Argentina, and a Doctor in Medicine from the University of Pretoria, South Africa.

From 1980 to 1989 he worked at the Department of Medical Oncology at the University of Pretoria, South Africa.

In 1989 he founded the Sandton Oncology Centre in Johannesburg and was its Medical Oncology Director from 12/2017 when he retired from active clinical practice.

Dr Vorobiof is a member of many national and international oncologic societies:
He served on the International Affairs Committee of ASCO (1999 – 2001), and was a member of the ASCO International Strategic Planning Task Force (2001).

He was the ESMO Regional Representative (Sub-Saharan Countries, 2005 – 11), and a member of the ESMO Developing Countries Task Force from 2004 – 07.

Since 2004 he has been a Faculty Member of the International Oncology Board, Faculty of 1000 (Medicine) and since 01/2019 the Section Head for the Oncologic Drugs section.

Since 2017 he is a member of the European School of Oncology (ESO) Core Faculty in Breast Cancer and Malignant Melanoma, and an ESO Visiting Professor.

Dr Vorobiof is on the Editorial Board of various international oncologic medical journals (The Breast, Cancer and Chemotherapy Reviews, The ASCO Post, Journal of Global Oncology).

From 2008 – to 2014 he was an Associate Editor for the Annals of Oncology. From 2008-to 18 he was the Editor of Annals of Oncology, Southern Africa Excerpts.

From 2016-to 20 he was the Editor of Live for Life, a South African magazine for cancer patients and their families.

Dr Vorobiof was a founder member and served twice as Chairman (1999 – 2005) of the South African Society of Medical Oncology (SASMO).

He was the founder and past Chairman of the South African Melanoma Advisory Board (SAMAB), founder member and past Director of the South African Oncology Consortium (SAOC), as well as founder member and past Director of the Prostate Cancer Foundation of South Africa.

Dr Vorobiof has been involved in clinical research nationally and internationally with a number of International Cooperative Oncology Groups [International Breast Cancer Study Group (IBCSG), the Breast International Group (BIG), the WHO Melanoma Group, European Organization for Research and Treatment of Cancer (EORTC), the Swiss Group for Clinical Cancer Research (SAKK)] , and with other multicentric co-operative clinical trials in South Africa, Europe, and North America, as well as Pharmaceutical companies sponsored clinical trials.

He has published more than 120 research articles in international peer-reviewed medical oncology journals and has presented at numerous national and international congresses.

He is an active panelist and Faculty member of the Advanced Breast Cancer (ABC 2-5) International Consensus Conference.

Dr Vorobiof has been the convener of several International and National Oncology congresses in South Africa and other countries with ESO, as well as with SASMO, SAMAB and the Melanoma World Society (MWS).

In 2008 he received the Gynecological Oncology Award (Dept. of Gynecology, University of the Witwatersrand).
2013 Dr Vorobiof was the Sealy-Falkson Honorary Lecturer at the 16th National Congress of SASMO / SASCRO.

Since 04/2018 Dr Vorobiof is the Medical Director of Belong.life, the largest international social and professional patient engagement and treatment management platform.